SFM
ACHN

Sphera Funds Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Sphera Funds Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-300,000
Closed -$1.35M – 160
2017
Q3 		$1.35M Buy
+300,000
New +$1.33M 0.19% 97
2015
Q2 		– Sell
-65,538
Closed -$646K – 171
2015
Q1 		$646K Sell
65,538
-60,000
-48% -$749K 0.07% 140
2014
Q4 		$1.54M Buy
+125,538
New +$1.53M 0.26% 98
2014
Q3 		– Sell
-150,000
Closed -$1.14M – 151
2014
Q2 		$1.14M Buy
+150,000
New +$599K 0.28% 75

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sphera Funds Management's ACHN Position: Q4 2017 in Review

Sphera Funds Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2017, closing a stake of 300,000 shares — an estimated $1.35M sold.

Sphera Funds Management first reported a position in ACHN in Q2 2014 and held it in 4 quarters. The position peaked at $1.54M in Q4 2014. 149 funds tracked by Wall St. Rank hold ACHN as of Q4 2017.

  • Sphera Funds Management reported no remaining Achillion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Sphera Funds Management sold 300,000 Achillion Pharmaceuticals shares in Q4 2017, an estimated $1.35M.
  • Sphera Funds Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 4 quarters.
  • Sphera Funds Management's Achillion Pharmaceuticals position peaked at $1.54M in Q4 2014.
  • 149 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2017.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.